EBITDA for Quest Diagnostics (DGX)
According to Quest Diagnostics's latest reported financial statements, the company's current EBITDA (TTM) is $1.98B USD. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Currently viewingEBITDASwitch metric
TTM (last 4 quarters)
$1.98B
YoY change
+15.8%
5Y CAGR
-1.9%
Peak year (2021)
$3.16B
Cumulative EBITDA
$38.95B
EBITDA history chart for Quest Diagnostics (DGX) from 1996 to 2025
EBITDA history table for Quest Diagnostics (DGX) from 1996 to 2025
| Fiscal year | Period ended | Reported | EBITDA | YoY |
|---|---|---|---|---|
| 2025 | $2.19B | +15.8% | ||
| 2024 | $1.89B | +9.4% | ||
| 2023 | $1.73B | -4.8% | ||
| 2022 | $1.82B | -42.4% | ||
| 2021 | $3.16B | +31.0% | ||
| 2020 | $2.41B | +52.1% | ||
| 2019 | $1.58B | +12.9% | ||
| 2018 | $1.40B | -3.4% | ||
| 2017 | $1.45B | -1.8% | ||
| 2016 | $1.48B | -4.9% | ||
| 2015 | $1.55B | +19.2% | ||
| 2014 | $1.30B | -27.3% | ||
| 2013 | $1.79B | +17.7% | ||
| 2012 | $1.52B | +17.0% | ||
| 2011 | $1.30B | -17.9% | ||
| 2010 | $1.59B | -2.8% | ||
| 2009 | $1.63B | +8.7% | ||
| 2008 | $1.50B | +12.9% | ||
| 2007 | $1.33B | +0.3% | ||
| 2006 | $1.33B | +12.0% | ||
| 2005 | $1.18B | +12.8% | ||
| 2004 | $1.05B | +10.4% | ||
| 2003 | $950.36M | +31.3% | ||
| 2002 | $723.84M | +29.5% | ||
| 2001 | $559.12M | +23.7% | ||
| 2000 | $452.11M | +86.2% | ||
| 1999 | $242.80M | +48.9% | ||
| 1998 | $163.10M | +7.9% | ||
| 1997 | $151.10M | -130.1% | ||
| 1996 | -$502.19M | — |
EBITDA values are taken from Quest Diagnostics's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
In 2025, Quest Diagnostics (DGX) EBITDA totalled $2.19B – grew 15.8% year-over-year.
Through 2020–2025 (5 years), Quest Diagnostics EBITDA delivered a -1.9% annualised rate; sustaining 2 straight years of year-over-year growth.
Quest Diagnostics EBITDA plunged from $3.16B in 2021 to $2.19B in 2025, a 30.5% drawdown.
The highest annual EBITDA of $3.16B was reported in 2021. The lowest in the available history was -$502.19M in 1996.
Quest Diagnostics (DGX) sits 9th of 8 Healthcare peers we track on this metric, against a peer median of $24.21B.
Quest Diagnostics EBITDA by Year
Quest Diagnostics EBITDA 2025: $2.19B
Quest Diagnostics EBITDA in 2025 was $2.19B, grew 15.8% from 2024.
Quest Diagnostics EBITDA 2024: $1.89B
Quest Diagnostics EBITDA in 2024 was $1.89B, grew 9.4% from 2023.
Quest Diagnostics EBITDA 2023: $1.73B
Quest Diagnostics EBITDA in 2023 was $1.73B, edged down 4.8% below 2022.
Quest Diagnostics EBITDA 2022: $1.82B
Quest Diagnostics EBITDA in 2022 was $1.82B, plunged 42.4% below 2021.
Quest Diagnostics EBITDA 2021: $3.16B
Quest Diagnostics EBITDA in 2021 was $3.16B.
See more financial history for Quest Diagnostics (DGX).
Sector peers — EBITDA
Companies in the same sector as Quest Diagnostics, ranked by their latest EBITDA.
| Company | EBITDA | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $156.73B | Healthcare |
| Johnson & Johnson (JNJ) | $41.05B | Healthcare |
| Eli Lilly and Company (LLY) | $27.94B | Healthcare |
| Merck & Co., Inc. (MRK) | $25.36B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $23.06B | Healthcare |
| AstraZeneca PLC (AZN) | $19.83B | Healthcare |
| AbbVie Inc. (ABBV) | $17.63B | Healthcare |
| Amgen Inc. (AMGN) | $15.84B | Healthcare |
Frequently asked questions
What is Quest Diagnostics's EBITDA?
- Latest reported EBITDA for Quest Diagnostics (DGX) is $1.98B (period ending March 31, 2026).
How has Quest Diagnostics EBITDA changed year-over-year?
- Quest Diagnostics (DGX) EBITDA changed +15.8% year-over-year on the latest annual filing.
What is the long-term growth rate of Quest Diagnostics EBITDA?
- Quest Diagnostics (DGX) EBITDA compound annual growth rate is -1.9% over the most recent 5 years available.
When did Quest Diagnostics EBITDA hit its highest annual value?
- Quest Diagnostics EBITDA reached its highest annual value of $3.16B in 2021.
What was Quest Diagnostics EBITDA in 2024?
- Quest Diagnostics (DGX) EBITDA in 2024 was $1.89B.
What was Quest Diagnostics EBITDA in 2025?
- Quest Diagnostics (DGX) EBITDA in 2025 was $2.19B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
DGX Overview
Company profile, financial tools, and key metrics
DGX Revenue Counter
Earns $357.62 every second. See per minute, hour, and day.
DGX Earnings Counter
Earns $32.47 per second net profit. See per minute, hour, and day.
DGX Economic Scale
Exceeds Monaco's GDP. Compare with world economies.
DGX What If Invested
What if you had invested $1,000? See historical returns from any date.
DGX How It Makes Money
Discover visual breakdown of $11.28B in revenue — where it comes from and where it goes.
DGX Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
DGX Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
DGX Daily Price Character
Steady · 50.6% historical win rate (green days). Streaks & record days.
DGX Buybacks
2.09% TTM buyback yield. Shareholder yield & SBC comparison.
DGX Stock Split History
2 splits on record. Dates, ratios, and cumulative multiple.
DGX Dividend Profile
Yield: 1.72%. Safety: 5/8. See full history.
DGX Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
DGX Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.